Charles River Laboratories Narrows FY23 Outlook Range; Q3 Results Top Estimates

RTTNews | 648天前
Charles River Laboratories Narrows FY23 Outlook Range; Q3 Results Top Estimates

(RTTNews) - While reporting financial results for the first quarter on Thursday, Charles River Laboratories International, Inc. (CRL) narrowed its earnings, adjusted earnings, revenue growth and organic revenue growth guidance range for the full-year 2023.

For fiscal 2023, the company now projects earnings in the range of $7.30 to $7.50 per share and adjusted earnings in the range of $10.50 to $10.70 per share on revenues growth of 2.5 to 3.5 percent, with organic revenues growth of 5.5 to 6.5 percent.

Previously, the company expected earnings in the range of $7.60 to $8.20 per share and adjusted earnings in the range of $10.30 to $10.90 per share on revenues growth of 2.5 to 4.5 percent, with organic revenues growth of 5.5 to 7.5 percent.

On average, analysts polled by Thomson Reuters expect the company to report earnings of $10.54 per share on revenue growth of 4.10 percent to $4.14 billion for the year. Analysts' estimates typically exclude special items.

For the third quarter, the company reported the net income attributable to common shareholders of $87.39 million or $1.69 per share, lower than $96.47 million or $1.88 per share in the prior-year quarter.

Excluding items, adjusted earnings for the quarter was $2.72 per share, compared to $2.63 per share in the year-ago quarter.

Total revenue for the quarter increased 3.8 percent to $1.03 billion from $989.16 million in the same quarter last year. Organic revenue growth was 4.1 percent.

The Street was looking for earnings of $2.37 per share on revenues of $1.0 billion for the quarter.

For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com

read more
Charles River Laboratories Slashes FY24 Outlook - Update

Charles River Laboratories Slashes FY24 Outlook - Update

While reporting financial results for the second quarter on Wednesday, Charles River Laboratories International, Inc. (CRL) slashed its earnings, adjusted earnings, revenue growth and organic revenue growth guidance for the full-year 2024.
RTTNews | 375天前
Charles River Labs Boosts FY23 Outlook As Q2 Results Top Estimates

Charles River Labs Boosts FY23 Outlook As Q2 Results Top Estimates

While reporting financial results for the first quarter on Thursday, Charles River Laboratories International, Inc. (CRL) raised its adjusted earnings, revenue growth and organic revenue growth guidance for the full-year 2023, to reflect the strong first-quarter financial performance and expectations for the remainder of the year that are largely consistent with its initial outlook.
RTTNews | 829天前
Charles River Labs Slashes FY22 Outlook; Q2 Adj. EPS Tops Estimates, Revenues Miss

Charles River Labs Slashes FY22 Outlook; Q2 Adj. EPS Tops Estimates, Revenues Miss

While reporting financial results for the second quarter on Wednesday, Charles River Laboratories International, Inc. (CRL) slashed its earnings, adjusted earnings, revenue growth and organic revenue growth guidance for the full-year 2022, due primarily to headwinds associated with the CDMO business, foreign exchange, and interest expense due to the rising interest rate environment.
RTTNews | 1110天前
Lower Open Predicted For Taiwan Stock Market

Lower Open Predicted For Taiwan Stock Market

The Taiwan stock market rebounded on Friday, one day after ending the five-day winning streak in which it had rallied more than 910 points or 3.9 percent. The Taiwan Stock Exchange now sits just above the 24,330-point plateau although it may head south again on Monday.
RTTNews | 14分钟前
Little Movement Expected For Singapore Stock Market

Little Movement Expected For Singapore Stock Market

The Singapore stock market has moved lower in two straight sessions, falling more than 40 points or 0.9 percent along the way. The Straits Times Index now sits just above the 4,230-point plateau and it's likely to remain in that neighborhood again on Monday.
RTTNews | 44分钟前